verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
Company profile
Ticker
VRCA
Exchange
Website
CEO
Ted White
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
VRCA stock data
Latest filings (excl ownership)
DEF 14A
Definitive proxy
19 Apr 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
29 Feb 24
8-K
Regulation FD Disclosure
8 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results
9 Nov 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results
8 Aug 23
8-K
Regulation FD Disclosure
27 Jul 23
8-K
Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
26 Jul 23
Latest ownership filings
4
Christopher G. Hayes
19 Mar 24
4
Gary Goldenberg
19 Mar 24
4
Terry Kohler
19 Mar 24
4
Joe Bonaccorso
19 Mar 24
4
Ted White
19 Mar 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
SC 13G
Avoro Capital Advisors LLC
14 Feb 24
4
JOSEPH EDELMAN
29 Dec 23
4
JOSEPH EDELMAN
26 Dec 23
4
JOSEPH EDELMAN
19 Dec 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 84.31 mm | 84.31 mm | 84.31 mm | 84.31 mm | 84.31 mm | 84.31 mm |
Cash burn (monthly) | (no burn) | (no burn) | 7.97 mm | 4.07 mm | 4.94 mm | 2.42 mm |
Cash used (since last report) | n/a | n/a | 53.11 mm | 27.11 mm | 32.89 mm | 16.11 mm |
Cash remaining | n/a | n/a | 31.20 mm | 57.20 mm | 51.42 mm | 68.20 mm |
Runway (months of cash) | n/a | n/a | 3.9 | 14.1 | 10.4 | 28.2 |
Institutional ownership, Q3 2023
39.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 68 |
Opened positions | 12 |
Closed positions | 9 |
Increased positions | 17 |
Reduced positions | 19 |
13F shares | Current |
---|---|
Total value | 58.37 bn |
Total shares | 16.53 mm |
Total puts | 10.10 k |
Total calls | 1.20 k |
Total put/call ratio | 8.4 |
Largest owners | Shares | Value |
---|---|---|
Perceptive Advisors | 5.04 mm | $19.58 bn |
Avoro Capital Advisors | 2.95 mm | $11.48 bn |
FMR | 1.50 mm | $5.85 bn |
Paul B Manning | 1.48 mm | $3.70 mm |
Vanguard | 1.23 mm | $4.77 bn |
BLK Blackrock | 1.05 mm | $4.08 bn |
Geode Capital Management | 416.79 k | $1.62 bn |
STT State Street | 382.74 k | $1.49 bn |
Caligan Partners | 259.59 k | $1.01 bn |
NTRS Northern Trust | 187.48 k | $728.35 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Mar 24 | Christopher G. Hayes | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 163,226 |
15 Mar 24 | Christopher G. Hayes | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.8 | 80,000 | 384.00 k | 80,000 |
15 Mar 24 | Goldenberg Gary | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 126,257 |
15 Mar 24 | Goldenberg Gary | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.8 | 80,000 | 384.00 k | 80,000 |
15 Mar 24 | Terry Kohler | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 74,416 |
15 Mar 24 | Terry Kohler | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.8 | 80,000 | 384.00 k | 80,000 |
15 Mar 24 | Joe Bonaccorso | Common Stock | Grant | Acquire A | No | No | 0 | 40,000 | 0.00 | 132,392 |
15 Mar 24 | Joe Bonaccorso | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.8 | 80,000 | 384.00 k | 80,000 |
15 Mar 24 | Ted White | Common Stock | Grant | Acquire A | No | No | 0 | 112,500 | 0.00 | 282,590 |
15 Mar 24 | Ted White | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.8 | 225,000 | 1.08 mm | 225,000 |
News
Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $8 Price Target
10 Apr 24
Verrica Pharmaceuticals' Lead Product, Ycanth, Has Received New Chemical Entity Status And A Listing In The Orange Book From The FDA, Providing A Minimum of Five Years Of Regulatory Exclusivity
26 Mar 24
Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $8 Price Target
1 Mar 24
HC Wainwright & Co. Maintains Buy on Verrica Pharmaceuticals, Raises Price Target to $13
1 Mar 24
Verrica Pharmaceuticals Q4 EPS $(0.53), Inline, Sales $1.99M Beat $910.00K Estimate
29 Feb 24
Press releases
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
26 Mar 24
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
8 Mar 24
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
29 Feb 24
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
27 Feb 24